We are live on ! Find out more
OZEM

Roundhill GLP-1 & Weight Loss ETF

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 0%
Negative

Positive
ETF Trends
8 days ago
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
Positive
Zacks Investment Research
9 days ago
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
Positive
Zacks Investment Research
1 month ago
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
Positive
MarketBeat
2 months ago
3 Ways to Invest in the Growing GLP-1 Weight Loss Market
Weight loss drugs are big business, with the GLP-1 receptor agonist market expected to nearly triple in size to $185 billion by 2033, a compound annual growth rate of about 12.4%. Although increasingly a global medical phenomenon, the bulk of the market still exists in the United States, and domestic investors can get in on the action by targeting companies that manufacture these powerful drugs.
3 Ways to Invest in the Growing GLP-1 Weight Loss Market
Positive
Seeking Alpha
2 months ago
Oral GLP-1 Is Here - Have Credit Markets Caught Up?
For the past two years, GLP-1 medications have been a fixture of consumer trend analysis, discussed by everyone from CNBC to sell-side strategists to management consultants. Real apparel expenditure outperformed total consumer spending by approximately 400 basis points per month on average in 2025, a trend our analysis attributes in part to GLP-1-driven wardrobe replacement. The oral pill launch likely means the population of GLP-1 users will grow materially over the next several years.
Oral GLP-1 Is Here - Have Credit Markets Caught Up?
Negative
Zacks Investment Research
4 months ago
Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook
Novo Nordisk slides 15% on a cautious 2026 sales outlook, but buybacks, leadership moves and Wegovy expansion put its ETFs in focus.
Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook
Positive
Seeking Alpha
4 months ago
OZEM Vs. THNR: Which Is The Better ETF In The GLP-1 And Weight Loss Space?
I recommend buying the Roundhill GLP-1 & Weight Loss ETF (OZEM) for strategic exposure to the weight loss drug sector. OZEM offers diversified access to leading GLP-1 innovators like Novo Nordisk and Eli Lilly, with a 34x earnings multiple versus Eli Lilly's 45x. AI-driven drug discovery, highlighted by the Nvidia-Eli Lilly partnership, is a major catalyst for sector growth and future upside.
OZEM Vs. THNR: Which Is The Better ETF In The GLP-1 And Weight Loss Space?
Positive
MarketBeat
5 months ago
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All
After a lackluster first half of 2025, healthcare stocks staged a comeback, posting the best performance among the 11 S&P 500 sectors over the past six months.
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All
Positive
ETF Trends
5 months ago
New Year, New Strategy: Navigating Weight Loss ETFs
With the start of 2026, the annual focus on weight loss resolutions presents a timely opportunity for financial advisors to discuss the investment potential of GLP-1 agonists with their clients. This class of drugs has fundamentally altered the healthcare sector's growth projections.
New Year, New Strategy: Navigating Weight Loss ETFs
Positive
Zacks Investment Research
6 months ago
6 Top-Performing ETF Areas of Last Week
Cannabis, metals, space and health care led ETF gains last week. WEED, CNBS, SIL, UFO, GDXJ, PLTM and OZEM outperformed despite tech weakness.
6 Top-Performing ETF Areas of Last Week